AURX 8-K
Nuo Therapeutics, Inc. (AURX)
8-K
2022-06-28
For: 2022-06-23
View Original
Added on
April 06, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 23, 2022
(Exact name of Registrant as Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
|
of Incorporation)
|
File Number)
|
Identification No.)
|
(Address of Principal Executive Offices) (Zip Code)
(346 ) 396-4770
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 8.01 Other Events.
On June 23, 2022, Nuo Therapeutics, Inc. (the “Company”) entered into an Exclusive Sales Agent and Services Agreement (the “Agreement”) with Pacific Medical, Inc. (“PacMed”) pursuant to which PacMed was appointed an exclusive distributor for the Company’s Aurix System product within a defined territory. The Agreement also covers any future products sold by the Company but under commercial terms to be agreed between the parties. The PacMed territory covers the states of Washington, Oregon, Idaho, Montana, Wyoming, most of California, the northern half of Nevada, plus Alaska.. The term of the Agreement extends for five (5) years subject to standard termination provisions including the failure to meet agreed sales quotas. The compensation under the Agreement consists of a commission percentage on product sales plus an annual bonus opportunity of a further percentage of product sales provided annual sales quotas are exceeded by an agreed percentage increment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Nuo Therapeutics, Inc.
|
|||
|
By:
|
/s/ David E. Jorden
|
||
|
David E. Jorden
|
|||
|
Chief Executive and Chief Financial Officer
|
|||
Date: June 28, 2022